Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia. We show 43 historical shares outstanding datapoints in our RARE shares outstanding history coverage, used to compute RARE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RARE market cap history over the course of time is important for investors
interested in comparing RARE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RARE versus a peer is one thing; comparing
RARE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RARE can fluctuate over the course of history.
With this page we aim to empower investors researching RARE by allowing them to research the RARE market cap history. |
Free RARE Email Alerts:
Video: The Importance of Market Cap
